-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In 1957, when metformin was first marketed in France as an alternative to insulin for lowering blood sugar, no one could have imagined that this inconspicuous drug at the time has become a "star" drug more than half a century later
As a derivative of the natural product goatine, metformin is not only widely used in clinical treatment as a first-line drug for the treatment of type 2 diabetes, but also can reduce the body weight of diabetic patients, reduce liver fat content, and reduce the risk of diabetes-induced cancer
Countless people have benefited from this ancient drug, but for scientists, a key question has remained unanswered: What is the target of metformin? In other words, we know metformin works, but exactly how it works is not clear
Previous studies have proposed several candidate theories for the mechanism of action of metformin
Evidence suggests that metformin works by inhibiting a class of mitochondrial electron transport chain complexes that activate AMPK
Now, this "mystery of the century" has finally ushered in the answer
In the journal "Cell Metabolism" 6 years ago, a study led by Professor Lin Shengcai's team proposed that metformin may activate AMPK protein through the lysosomal pathway
To this end, the authors synthesized photosensitive metformin chemical probes—when metformin molecules bind to a protein molecule, they can be detected by tags on the probe
Subsequently, the research team sequentially inhibited the expression of these 113 proteins through gene silencing, and finally found a distinctive protein-only when the expression of presenilin enhancer 2 (PEN2, a subunit of γ-secretase) was inhibited , cells become insensitive to metformin treatment, and metformin cannot activate AMPK
▲Metformin binds to PEN2 to activate AMPK (Image source: Reference [1])
Next, the research team revealed the pathway by which metformin works based on this newly discovered target
▲ Molecular pathway of metformin’s effect (Image source: Reference [1])
In subsequent animal experiments, the research team further verified the above mechanism
Normally, metformin mediates a decrease in liver fat content
Through this series of experimental designs, this study is the first to clearly demonstrate the mechanism of action of metformin at the molecular level
References:
[1] Ma, T.
[2] Chen-Song Zhang et al.
[3] Breakthrough! Lin Shengcai and Deng Xianming's team collaborated to decipher metformin targets.